A vs RVTY vs RGEN Stock Comparison

Agilent Technologies, Revvity and Repligen Prices as of Nov 2, 2026 Peers: Industry group
1 more company in this comparison (DHR) Create a free account to keep reading and compare up to 10 companies.
A Agilent Technologies, Inc.
$172.02 +2.6% 1M +17.5% 1Y
Market cap
$48.50B
P/E
33.7x
Revenue (TTM)
$7.37B
Div. yield
0.60%
Life Sciences Tools Healthcare
9 wins
RVTY Revvity, Inc.
$151.70 +0.1% 1M +62.1% 1Y
Market cap
$16.93B
P/E
71.3x
Revenue (TTM)
$2.91B
Div. yield
0.18%
Life Sciences Tools Healthcare
1 win
RGEN Repligen Corp
$172.95 -4.8% 1M +16.0% 1Y
Market cap
$9.76B
P/E
–
Revenue (TTM)
$805.61M
Div. yield
–
Life Sciences Tools Healthcare
2 wins

Head to Head

12 decided of 12

Agilent Technologies leads on 9 of the 12 questions below (Agilent Technologies 9, Repligen 2, Revvity 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionARVTYRGENLeader
Larger companyMarket capitalisation $48.50B $16.93B $9.76B A
Cheaper on earningsLower P/E, profitable companies only 33.7x 71.3x -826.6x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.3x 29.7x 89.1x A
Faster revenue growthRevenue growth, trailing twelve months +8.6% +4.1% +13.8% RGEN
More profitableNet margin, trailing twelve months 19.5% 8.2% -1.5% A
Better return on capitalReturn on invested capital 13.1% 3.1% 0.0% A
Less leveragedLower net debt / EBITDA 1.1x 2.8x -2.8x RGEN
Higher dividend yieldTrailing dividend yield 0.60% 0.18% — A
Better 1-year returnPrice return, last 12 months +17.5% +62.1% +16.0% RVTY
Better 5-year returnAnnualised price return, 5 years +1.7%/yr -2.7%/yr -10.0%/yr A
Less volatileAnnualised volatility, 1 year 32.6% 40.1% 46.5% A
Higher overall scoreMean of the five percentile scores vs peers 62/100 58/100 54/100 A

Percentile Scorecard

ARVTYRGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisARVTYRGEN
Valuation 57 #98 of 227 71 #67 of 227 51 #111 of 227
Growth 36 #141 of 220 27 #160 of 220 25 #165 of 220
Profitability 91 #19 of 209 80 #43 of 209 66 #71 of 209
Financial Health 56 #107 of 240 47 #127 of 240 80 #49 of 240
Shareholder Returns 68 #45 of 138 64 #50 of 138 50 #70 of 138
Overall 62 58 54
  • A ranked among 247 companies in Medical Devices and Diagnostics
  • RVTY ranked among 247 companies in Medical Devices and Diagnostics
  • RGEN ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodARVTYRGENSPY
1 month +2.6%+0.1%-4.8% -2.3%
3 months +23.0%+31.7%+17.6% -0.7%
6 months +53.3%+75.4%+46.3% +4.8%
Year to date +26.4%+56.8%+5.5% +10.3%
1 year +17.5%+62.1%+16.0% +10.3%
3 years +57.8%+72.1%+15.0% +73.0%
3 years, per year +16.4%+19.8%+4.8% +20.1%
5 years +8.7%-12.9%-40.8% +61.9%
5 years, per year +1.7%-2.7%-10.0% +10.1%
10 years +297.6%+203.3%+512.4% +258.6%
10 years, per year +14.8%+11.7%+19.9% +13.6%

Risk

MeasureARVTYRGENSPY
Volatility, 1Y 32.6%40.1%46.5% 12.8%
Downside volatility, 1Y 27.9%36.6%46.9% 12.8%
Beta vs S&P 500, 1Y 0.911.251.26 1.00
Return / volatility, 1Y 0.541.550.34 0.80
Max drawdown, 5Y -39.6%-59.2%-64.8% -25.4%
From 52-week high -5.2%-8.5%-11.1% -3.5%
52-week high $181.54$165.78$194.57 $779.14
52-week low $110.24$82.26$102.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleARVTYRGEN
P/E now vs peer median 33.7xmedian 28.4x 71.3xmedian 28.4x -826.6xmedian 28.4x
P/S now vs peer median 6.6xmedian 3.0x 5.8xmedian 3.0x 12.1xmedian 3.0x
EV/EBITDA now vs peer median 26.5xmedian 18.0x 24.6xmedian 18.0x 86.2xmedian 18.0x
P/FCF now vs peer median 38.3xmedian 25.0x 29.8xmedian 25.0x 91.4xmedian 25.0x
P/B now vs peer median 6.6xmedian 2.3x 2.3xmedian 2.3x 4.7xmedian 2.3x
PEG now vs peer median 3.43median 0.93 -2.29median 0.93 29.08median 0.93

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsARVTYRGEN
Revenue $7.37B $2.91B $805.61M
Gross profit $3.97B $1.60B $430.67M
Operating income $1.64B $358.85M $18.24M
Net income $1.44B $237.55M -$11.80M
Free cash flow $1.27B $568.85M $106.72M
R&D $485.00M $215.83M $57.23M
EPS (diluted) $5.09 $2.13 $-0.21
Cash & equivalents $1.76B $1.02B $726.96M
Total debt $3.95B $3.21B $555.60M
Shares (diluted) 283.00M 111.63M 56.64M
Enterprise value $41.39B $13.19B $6.53B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricARVTYRGEN
P/E 33.7x 71.3x -826.6x
P/FCF 38.3x 29.8x 91.4x
P/Operating cash flow 30.1x 26.5x 75.1x
P/S 6.6x 5.8x 12.1x
P/B 6.6x 2.3x 4.7x
P/Tangible book 7.5x 3.4x 5.5x
EV/EBITDA 26.5x 24.6x 86.2x
EV/EBIT 30.9x 53.3x 518.2x
EV/Revenue 6.9x 6.6x 11.7x
EV/FCF 40.0x 33.6x 88.6x
EV/Operating cash flow 31.5x 29.9x 72.8x
PEG (3Y EPS CAGR) 3.43 -2.29 29.08

Growth

14 metrics
MetricARVTYRGEN
Revenue growth (1Y) 8.6% 4.1% 13.8%
Revenue CAGR (3Y) 1.8% 0.9% 7.3%
Gross profit growth (1Y) 11.2% 2.3% 33.0%
Gross profit CAGR (3Y) 3.7% -0.4% 13.3%
Operating income growth (1Y) 13.5% -5.5% 2,185%
Operating income CAGR (3Y) 5.1% -3.7% -40.5%
Net income growth (1Y) 18.0% -16.7% -779.2%
Net income CAGR (3Y) 8.3% -33.8% -28.4%
EPS growth (1Y) 18.9% -12.3% -777.9%
EPS CAGR (3Y) 9.8% -31.2% -28.4%
Operating cash flow growth (1Y) 7.6% 6.2% -0.8%
Operating cash flow CAGR (3Y) -1.9% 86.9% -4.0%
Free cash flow growth (1Y) 16.5% 9.5% -3.0%
Free cash flow CAGR (3Y) -3.7% 64.8% 1.8%

Profitability

14 metrics
MetricARVTYRGEN
Gross margin 53.8% 55.0% 53.5%
EBITDA margin 25.9% 26.6% 13.6%
Operating margin 22.2% 12.3% 2.3%
Pretax margin 22.5% 9.0% 1.0%
Net margin 19.5% 8.2% -1.5%
FCF margin 17.2% 19.5% 13.2%
Operating cash flow margin 21.8% 21.9% 16.1%
Return on equity 19.9% 3.3% -0.6%
Return on assets 10.7% 2.0% -0.4%
Return on invested capital 13.1% 3.1% 0.0%
Return on capital employed 14.6% 3.3% 0.6%
Asset turnover 0.5x 0.2x 0.3x
Cash conversion (OCF / net income) 1.1x 2.7x -11.0x
Stock comp / revenue 1.8% 0.8% 4.2%

Financial Health

11 metrics
MetricARVTYRGEN
Debt / assets 28.3% 26.6% 19.0%
Debt / equity 0.5x 0.4x 0.3x
Net debt / EBITDA 1.1x 2.8x -2.8x
Debt / FCF 3.1x 5.6x 5.2x
Liabilities / assets 47.3% 40.0% 28.5%
Equity / assets 52.7% 60.0% 71.5%
Interest coverage 15.5x 3.7x 0.8x
Current ratio 2.1x 1.8x 9.9x
Quick ratio 1.4x 1.4x 8.1x
Cash ratio 0.8x 0.8x 6.9x
Altman Z-score 5.72 3.26 7.98

Shareholder Returns

7 metrics
MetricARVTYRGEN
Dividend yield 0.6% 0.2% –
Net buyback yield 0.6% 2.8% -0.2%
Shareholder yield 1.2% 3.0% -0.2%
Payout ratio (earnings) 19.9% 13.4% –
Payout ratio (FCF) 22.6% 5.6% –
Dividend growth (1Y) 2.1% -6.3% –
Dividend CAGR (3Y) 3.1% -6.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusARVTYRGEN
Forward P/E 26.3xFY2026 29.7xFY2026 89.1xFY2026
EPS, next fiscal year $6.54FY2026 $5.10FY2026 $1.94FY2026
EPS growth, next FY +17.0%FY2026 +0.8%FY2026 +13.5%FY2026
EPS growth, the year after +0.3% +11.0% +29.4%
Revenue, next fiscal year $7.87BFY2026 $2.98BFY2026 $773.94MFY2026
Revenue growth, next FY +15.3%FY2026 +4.0%FY2026 +4.8%FY2026
Revenue growth, the year after -5.6% -2.0% +35.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersARVTYRGEN
Held by institutions 92.6% 100.0% 100.0%
Institutions holding 1,126 547 483
Change in shares held, QoQ +3.2% -1.3% +1.2%
Institutions buying 603 303 273
Institutions selling 350 161 141
Buyers to sellers 1.72 1.88 1.94

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ARVTYRGEN
A 1.00 0.65 0.62
RVTY 0.65 1.00 0.61
RGEN 0.62 0.61 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, A, RVTY and RGEN?

Agilent Technologies (A) is the largest by market capitalisation: Agilent Technologies (A) $48.50B, Revvity (RVTY) $16.93B, Repligen (RGEN) $9.76B.

Which stock is cheaper, A, RVTY and RGEN?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Agilent Technologies (A) 33.7x, Revvity (RVTY) 71.3x, Repligen (RGEN) -826.6x). On next year's consensus earnings, Agilent Technologies (A) is cheapest (Agilent Technologies (A) 26.3x, Revvity (RVTY) 29.7x, Repligen (RGEN) 89.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Agilent Technologies (A) +8.6%, Revvity (RVTY) +4.1%, Repligen (RGEN) +13.8%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Agilent Technologies (A) 19.5%, Revvity (RVTY) 8.2%, Repligen (RGEN) -1.5%). On return on invested capital, Agilent Technologies (A) leads (Agilent Technologies (A) 13.1%, Revvity (RVTY) 3.1%, Repligen (RGEN) 0.0%).

Which stock has performed better?

Over the past year Revvity (RVTY) returned the most: Agilent Technologies (A) +17.5%, Revvity (RVTY) +62.1%, Repligen (RGEN) +16.0%. Over five years, Agilent Technologies (A) compounded fastest (Agilent Technologies (A) +1.7%/yr, Revvity (RVTY) -2.7%/yr, Repligen (RGEN) -10.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Agilent Technologies (A) has the highest dividend yield: Agilent Technologies (A) 0.60%, Revvity (RVTY) 0.18%. Repligen (RGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Agilent Technologies (A) has been the steadiest (Agilent Technologies (A) 32.6%, Revvity (RVTY) 40.1%, Repligen (RGEN) 46.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, A, RVTY and RGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 9. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.